AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04584684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 27% Ethanol plus essential oils
Description: Over-the-counter antiseptic mouth rinse
Study NCT04584684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% w/v Povidone-iodide
Description: Over-the-counter antiseptic mouth rinse
Study NCT04584684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.075% Cetylpyridinium Chloride
Description: Over-the-counter antiseptic mouth rinse
Study NCT02222376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Twice a day topical application
Study NCT02222376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Weekly ulcer debridement
Study NCT02222376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement
Description: Weekly ulcer debridement
Study NCT03333629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced early detection
Description: standardized screening
Study NCT04653649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSP-CAR30
Description: Anti-CD30 CAR T-cells
Study NCT01651325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT02297997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetylpyridinium chloride
Description: Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
Study NCT01571661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075A
Description: 20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
Study NCT01571661 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02506816 — intervention group
Intervention type: DRUG
Intervention: Olaparib
Description: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
Study NCT03167762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence and thermal imaging
Description: Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
Study NCT04269967 — intervention group
Intervention type: OTHER
Intervention: Receiving routine rehabilitation care via tele-rehabilitation system
Description: Drain care education, self-massage techniques and exercise (PT and OT)
Study NCT01096784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhIGF-I/rhIGFBP-3
Description: Continuous intravenous infusion
Study NCT03357484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet rich fibrin
Description: Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH \& Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
Study NCT03357484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood clot
Description: Natural blood clot formed within extraction socket
Study NCT02514356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Own adherence
Description: In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
Study NCT02514356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Own and group level adherence
Description: In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
Study NCT04619524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cervical mucus will be collected from patients undergoing IVF
Description: Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.
Study NCT04619524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos
Description: Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.
Study NCT01054443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lusutrombopag
Description: Tablet
Study NCT01651325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Description: oral
Study NCT00656864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
Study NCT02297997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group takes the placebo for the same period.
Study NCT02881502 — intervention group
Intervention type: OTHER
Intervention: severe asthma group
Description: No intervention
Study NCT03182673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7390
Description: SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
Study NCT02166567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS
Study NCT02166567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Swim-up
Description: Semen processing will be carried out with the conventional swim-up method.
Study NCT01739712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: There will be a consultation with families to help youth to be successful in extending their sleep.
Study NCT01739712 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Fixed Sleep Duration
Description: There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
Study NCT02525900 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Wound Infiltration
Description: Wound Infiltration with 0.25% Bupivacine
Study NCT02525900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Blocks
Description: bilateral TAP block with 0.25% Bupivacaine
Study NCT03182673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
Study NCT03182673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
Study NCT02049476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone pellet
Description: Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol.
Study NCT04490421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with Apatinib, Etoposide and Cisplatin
Description: Camrelizumab combined with Apatinib, Etoposide and Cisplatin
Study NCT02525900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Catheters
Description: bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine
Study NCT03022084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desyncra
Description: This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
Study NCT03022084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: Standard of Care
Study NCT03616652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill
Study NCT03616652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study NCT03616652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film sequence
Description: The experimental group watches a film about the power of placebo effects.
Study NCT03616652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Film sequence
Description: The control group watches a film about sleep.
Study NCT00504816 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK189075
Description: Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
Study NCT00504816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brevicon
Description: Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
Study NCT04495400 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracolumbar Fracture Fixation
Description: The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
Study NCT03301246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artimes Pro Low Profile Dilatation Catheter
Description: Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
Study NCT01404546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cost free pharmacotherapy
Description: Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
Study NCT03102541 — intervention group
Intervention type: OTHER
Intervention: None intervention
Study NCT04596046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid injecting
Description: Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
Study NCT04596046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: steroid injecting
Description: Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
Study NCT04273802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351 in cohort A
Description: Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1.
Study NCT04273802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351 in cohort B
Description: Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1.
Study NCT01889342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Study NCT01889342 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Study NCT01287260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040)
Description: BAYA1040_Nifedipine 40mg twice daily (BID)
Study NCT01287260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine (Adalat, BAYA1040)
Description: BAYA1040_Nifedipine 40mg once daily (OD)
Study NCT03429569 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cross linking
Description: Accelerated cross-linking procedure: (Total duration: 40 minutes)
Study NCT02978404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is administered to patients to a maximum of 2 year.
Study NCT02978404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
Study NCT04668482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS is switched off
Description: Spinal cord stimulator is switched off for 12 hours
Study NCT04668482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS is switched on
Description: Spinal cord stimulator is functioning
Study NCT01407068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500 collagenase clostridium histolyticum
Description: 2 concurrent injections (0.58 mg) into 2 cords on the same hand
Study NCT00933816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib, cisplatin, fluorouracil
Description: Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
Study NCT01610752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartMoms
Description: This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
Study NCT05195242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ATC code H02AB02
Study NCT05195242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: ATC code H02AB02
Study NCT02438293 — intervention group
Intervention type: OTHER
Intervention: rhinovirus diagnostics
Description: rhinovirus PCR on a nasopharyngeal swab
Study NCT01933269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Study NCT02534324 — intervention group
Intervention type: DRUG
Intervention: Antihypertensive meds
Description: Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
Study NCT03674385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
Study NCT03674385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
Study NCT03674385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
Study NCT00656864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03674385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: is a medication used to treat infertility in women who do not ovulate
Study NCT03674385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: is a medication used to treat infertility in women who do not ovulate
Study NCT02208466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
Study NCT02208466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
Study NCT02208466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
Study NCT02208466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Fluoxetine
Description: Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
Study NCT00792467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
Study NCT00609934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
Study NCT00609934 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy
Description: 3000cGy in 10 fractions
Study NCT02048501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resting Metabolic Rate (RMR)
Description: Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
Study NCT02048501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Duel-energy x-ray absorptiometry (DEXA)
Description: During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
Study NCT02048501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual Analog Scale (VAS)
Description: Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
Study NCT02048501 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal Stimulation Test
Description: Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
Study NCT01391026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced patient-centered care
Description: The experimental arm will be referred to a multi-disciplinary clinic
Study NCT04187612 — intervention group
Intervention type: DEVICE
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: BIA will be used to determine total body water
Study NCT02450656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Tablet
Study NCT02450656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Capsule
Study NCT02450656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT04325126 — intervention group
Intervention type: OTHER
Intervention: Exposure factors
Description: Exposure factors，such as diet，exercise，environment
Study NCT03852901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin (Jardiance) 25 mg
Description: Oral empagliflozin 25 mg/day x 14 days